| Drug / Therapy | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in P |
| Indication | — |
| Decision Type | Phase 1 |
| Trial Phase | Phase 1 |
| ClinicalTrials.gov | NCT04626674 |
Sarepta Therapeutics (SRPT) operates in the Gene Therapy sector. The current BTS Score is 62 (Grade: C).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Phase 1 date for A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in P by Sarepta Therapeutics (SRPT) is scheduled for December 31, 2027. This is the target date for the FDA to make a decision on this application.
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in P is being developed by Sarepta Therapeutics for the treatment of its target indication. It is currently in Phase 1 clinical trials.
If A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in P receives FDA approval, Sarepta Therapeutics (SRPT) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 1 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for SRPT on DilutionWatch at dilutionwatch.com/stock/SRPT.html.
You can view the full BiotechSign company profile for Sarepta Therapeutics (SRPT) at biotechsign.com/app/company/SRPT, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.